Suppression of ovarian cancer by muscle‐mediated expression of soluble VEGFR‐1/Flt‐1 using adeno‐associated virus serotype 1‐derived vector

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International Journal of Cancer

• Publication date

  2007-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.22307PMID 17066424
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.

  2004cited by this paper
• Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues

  2004cited by this paper
• Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I.

  2004cited by this paper
• Cancer Statistics, 2004

  2004cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• Why did p53 gene therapy fail in ovarian cancer?

  2003cited by this paper
• Suppression of cell migration in ovarian cancer cells mediated by PTEN overexpression.

  2003cited by this paper
• Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.

  2003cited by this paper
• Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria*

  2003cited by this paper
• The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

  2003cited by this paper
• A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.

  2003cited by this paper
• Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

  2002cited by this paper
• A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

  2002cited by this paper
• Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.

  2002cited by this paper
• Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor

  2002cited by this paper
• Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.

  2002cited by this paper
• The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.

  2002cited by this paper
• Suppression of tumor growth through disruption of hypoxia-inducible transcription

  2000cited by this paper
• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  2000cited by this paper
• Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.

  2000cited by this paper
• Cloning and Characterization of Adeno-Associated Virus Type 5

  1999cited by this paper
• Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

  1999cited by this paper
• Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

  1999cited by this paper
• Gene Therapy Vectors Based on Adeno-Associated Virus Type 1

  1999cited by this paper
• Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells

  1999cited by this paper
• Purification of Recombinant Adeno-Associated Virus by Iodixanol Gradient Ultracentrifugation Allows Rapid and Reproducible Preparation of Vector Stocks for Gene Transfer in the Nervous System

  1999cited by this paper
• Adeno-associated virus vectors can be efficiently produced without helper virus

  1998cited by this paper
• Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2

  1998cited by this paper
• Recombinant adeno-associated virus for muscle directed gene therapy

  1997cited by this paper
• Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles

  1997cited by this paper
• Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptor‐1 (Flt‐1 Tyrosine Kinase)

  1997cited by this paper
• A novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome.

  1997cited by this paper
• Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.

  1996cited by this paper
• Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.

  1996cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector

  1996cited by this paper
• Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors

  1996cited by this paper
• Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3.

  1996cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper
• Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.

  1993cited by this paper
• Evaluation of selected prognostic factors in ovarian cancer.

  1993cited by this paper
• Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Surgery in advanced ovarian carcinoma: is there proof to show the benefit?

  1988cited by this paper
• Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor.

  1978cited by this paper
• Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

  1977cited by this paper

• AAV for ovarian cancer gene therapy

  2025cites this paper
• VEGF—Virus Interactions: Pathogenic Mechanisms and Therapeutic Applications

  2024cites this paper
• Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment.

  2024cites this paper
• Screening and identification of key biomarkers associated with endometriosis using bioinformatics and next generation sequencing data analysis

  2024cites this paper
• AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma

  2022cites this paper
• Diagnostic Value of Circulating PIGF in Combination with Flt-1 in Early Cervical Cancer

  2020cites this paper
• Recent Progress in Gene Therapy for Ovarian Cancer

  2018cites this paper
• Anti-angiogenesis gene therapy for hepatocellular carcinoma via systemic injection of mesenchymal stem cells engineered to secrete soluble Flt-1

  2017cites this paper
• Gene therapy in the treatment of human cancer

  2017cites this paper
• Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy

  2016cites this paper
• Engineering of Novel Adeno-Associated Virus Vectors for Gene Therapy Applications

  2016cites this paper
• Adeno-associated virus (AAV) vectors in cancer gene therapy.

  2016cites this paper
• Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors

  2016cites this paper
• The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival

  2015cites this paper
• Suppression of lymph node and lung metastases of endometrial cancer by muscle‐mediated expression of soluble vascular endothelial growth factor receptor‐3

  2013cites this paper
• Antiangiogenic gene therapy with soluble VEGF‐receptors ‐1, ‐2 and ‐3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma

  2012cites this paper
• Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

  2011cites this paper
• Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles.

  2011cites this paper
• Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.

  2011cites this paper
• Development of a mouse model for lymph node metastasis with endometrial cancer

  2011cites this paper
• Antiangiogenic gene therapy of solid tumor by systemic injection of polyplex micelles loading plasmid DNA encoding soluble flt-1.

  2010cites this paper
• Future Prospects and Challenges of Antiangiogenic Cancer Gene Therapy

  2010cites this paper
• Polyplex nanomicelle promotes hydrodynamic gene introduction to skeletal muscle.

  2010cites this paper
• Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival.

  2009cites this paper
• 8. Gene-based Treatment

  2009cites this paper
• Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

  2009cites this paper
• Turning the gene tap off; implications of regulating gene expression for cancer therapeutics

  2008cites this paper
• [Gene therapy using AAV].

  2007cites this paper
• Gene Therapy and the Evolution of Cancer Treatment

  2007cites this paper
• Gene therapy using AAV vectors

  2007cites this paper
• Anti-angiogenic gene therapy of cancer: current status and future prospects.

  2007cites this paper